肠康颗粒对腹泻型肠易激综合征大鼠的药效学研究

石磊; 沈明勤; 王志刚; 罗宇慧; 王颖钰; 李雪; 鞠建明; 李松林

肠康颗粒对腹泻型肠易激综合征大鼠的药效学研究

南京中医药大学附属中西医结合医院、江苏省中医药研究院中药药理室，江苏南京 210028

计量
- 文章访问数: 946
- HTML全文浏览量: 7
- PDF下载量: 629
- 被引次数: 0
出版历程
- 刊出日期: 2016-05-10

Pharmacodynamics of Changkang Granules in IBS-D Rats

摘要

摘要: 目的观察肠康颗粒对腹泻型肠易激综合征(IBS-D)模型大鼠的治疗作用，初步探讨其作用机制。方法乳大鼠出生后第8~21天，每天接受直结肠扩张刺激建立IBS-D内脏高敏感模型。60只大鼠随机分为6组，即正常对照组、模型对照组、阳性药组、肠康颗粒高、中、低剂量组，连续30d分别灌胃给药。进行腹壁撤退反射(AWR)评分。酶联免疫分析法检测大鼠血清降钙素基因相关肽（CGRP），大鼠结肠组织血管活性肠肽（VIP）。免疫组化法测定大鼠结肠黏膜层血管P物质（SP）阳性表达。结果与正常对照组比较，模型对照组大鼠AWR评分明显升高（P<0.01），血清CGRP含量、结肠组织VIP含量及结肠黏膜层血管SP阳性表达细胞数均显著降低（P<0.01）。与模型对照组比较，肠康颗粒各组大鼠的AWR评分明显降低（P<0.01），血清CGRP含量、结肠组织VIP含量明显升高（P<0.05～0.01），肠康颗粒中、高剂量组大鼠结肠黏膜层血管SP阳性表达细胞数明显的升高（P<0.05～0.01）。结论肠康颗粒对IBS-D大鼠有一定治疗作用。其作用机制可能与抑制IBS-D大鼠血清CGRP及结肠组织VIP含量的下降，抑制大鼠结肠黏膜层血管SP阳性表达下降有关。
- 肠康颗粒 /
- 腹泻型肠易激综合征 /
- 大鼠
Abstract: OBJECTIVE To study the therapeutic effect of Changkang Granules in rat with irritable bowel syndrome with Diarrhea （IBS-D) and investigate its mechanism． METHODS The model for IBS-D was established by colorectal distention daily in the neonatal rats between postnatal 8 and 21 days. Sixty SD rats were divided into the normal control group，the model group，positive control group，high-dose，middle-dose，low-dose Changkang Granules group．The treatment lasted for 30 days． The threshold of abdominal withdrawal reflex(AWR) during rectal distension was evaluated. The calcitonin gene-related peptide（CGRP） in serum， vasoactive intestinal peptide（VIP） in colon homogenates were evaluated by radioimmunoassay．Immunohistochemical SABC method to observe expression level of SP of colonic specimens. RESULTS Compared with the normal control group，AWR score increased（P<0.01）， The content of serum CGRP， VIP levels in colonic homogenate and expression level of SP in colon decreased markedly in the model group（P<0.01）. After administration with Changkang Granules， the AWR scores of the IBS-D rats were reduced（P<0.01）. The content of serum CGRP， colon VIP level and expression of SP in colon was increased significantly（P<0.05～0.01）. CONCLUSION The therapeutic effect of Changkang Granules on IBS-D rat is obvious． The mechanism could be related to inhibition against the excessive decrease of serum CGRP， colon VIP and expression level of SP in colon in IBS-D rats．
- Changkang Granules /
- irritable bowel syndrome with diarrhea （IBS-D) /
- rat

HTML全文

参考文献(16)

[1]	Chang JY， Talley NJ. An update on irritable bowel syndrome: from diagnosis to emerging therapies[J]. Curr Opin Gastroenterol， 2011， 27(1): 72-78.
[2]	中华中医药学会脾胃病分会．肠易激综合征中医诊疗共识意见[J]．中华中医药杂志，2010，25(7)：1062-1065.
[3]	Spleen and Stomach Diseases Branch of China Association of Chinese Medicine. Consensus on standard management of irritable bowel syndrome in TCM[J]. China J Tradit Chin Med Pharm， 2010，25(7)：1062-1065.
[4]	陆敏，黄厚才，钟荣玲，等．肠康方对肠易激综合征内脏高敏感模型大鼠的作用[J]．中国中西医结合消化杂志，2012， 20（1）：15-18．
[5]	Lu M， Huang HC， Zhong RL， et al. Effect of changkang formula on visceral hypersensitivity in rats with irritable bowel syndrome[J]. Chin J Integr Tradit West Med Digest， 2012， 20(1):15-18.
[6]	Alchaer ED， Kawasaki M， Pasricha PJ. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development[J]. Gastroenterology， 2000， 119(5): 1276-1285.
[7]	韩真，王运东．腹泻型肠易激综合征模型大鼠肠道Cajal间质细胞的变化及意义[J]．中国病理生理杂志，2008， 24（11）：2263-2264， 2271．
[8]	Han Z， Wang YD. Change of interstitial cells of Cajal of the bowels and its significance in the diarrhea irritable bowel syndrome[J]. Chin J Pathophysiol， 2008， 24(11): 2263-2264， 2271.
[9]	Heymann-Mnnikes I， Arnold R， Florin I， et al. The combination of medical treatment plus multicomponent behavioral therapy is superior to medical treatment alone in the therapy of irritable bowel syndrome[J]. Am J Gastroenterol， 2000， 95(4): 981-994.
[10]	吕宏伟，俞小玲．肠易激综合征患者血NPY、SP的变化及意义[J]．放射免疫学杂志，2000， 13（3）：146-147．
[11]	Lü HW， Yu XL. Changes of NPY and SP in irritable bowel syndrome[J]. J Radioimmanol， 2000， 13(3): 146-147.
[12]	陈羽，罗和生，梁成柏，等．肠易激综合征血清中降钙素基因相关肽的变化[J]．胃肠病学和肝病学杂志，2011， 20（7）：653-655．
[13]	Chen Y， Luo HS， Liang CB， et al. Changes of calcitonin gene-related peptide in irritable bowel syndrome[J]. Chin J Gastroenterol Hepatol， 2011， 20(7): 653-655.
[14]	Park JH， Rhee PL， Kim G， et al. Enteroendocrine cell counts correlate with visceral hypersensitivity in patients with diarrhoea-predominant irritable bowel syndrome[J]. Neurogastroenterol Motil， 2006， 18(7): 539-546.
[15]	Holzer P， Holzer-Petsche U. Tachykinin receptors in the gut: physiological and pathological implications[J]. Curr Opin Pharmacol， 2001， 1(6): 583-590.
[16]	Joo YE. Increased expression of brain-derived neurotrophic factor in irritable bowel syndrome and its correlation with abdominal pain[J]. J Neurogastroenterol Motil， 2013， 19(1): 109-111.